Naxitamab

Generic Name
Naxitamab
Brand Names
Danyelza
Drug Type
Biotech
Chemical Formula
-
CAS Number
1879925-92-4
Unique Ingredient Identifier
9K8GNJ2874
Background

Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside. Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within ne...

Indication

Naxitamab-gqgk is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of patients 1 year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

Associated Conditions
High risk, refractory Neuroblastomas of the bone or bone marrow, High risk, relapsed Neuroblastomas of the bone or bone marrow
Associated Therapies
-
Clinical Trials
Related News
investing.com
·

Earnings call: Y-mAbs Therapeutics reports Q3 2024 financials

Y-mAbs Therapeutics reported Q3 2024 net revenue of $18.5 million, a 10% decrease from Q3 2023, attributed to reduced product revenues and prior licensing revenue. Despite this, net revenue for the first nine months of 2024 remained stable at $61.2 million. The FDA-approved therapy DANYELZA saw a 5% drop in U.S. product revenues, influenced by Medicaid claim adjustments and increased competition. Y-mAbs maintained its full-year revenue guidance of $87-95 million, expecting to fall in the lower half of the range, and emphasized its strategic focus on drug development, including advancements in its SADA PRIT technology platform and a new licensing agreement for potential commercialization in Japan.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy